MDT

85.76

-0.01%↓

A

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

MDT

85.76

-0.01%↓

A

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

MDT

85.76

-0.01%↓

A

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

MDT

85.76

-0.01%↓

A

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

MDT

85.76

-0.01%↓

A

114.93

+1.35%↑

VEEV

174.59

-0.81%↓

HQY

82.54

+0.3%↑

PHR.US

8.36

+0.97%↑

Search

Ekso Bionics Holdings

Abrir

9.97 -0.5

Visão Geral

Variação de preço das ações

24h

Atual

Mín

9.97

Máximo

9.97

Indicadores-chave

By Trading Economics

Rendimento

-3.3M

-4.7M

Vendas

-1.1M

3.1M

EPS

-1.46

Margem de lucro

-148.854

Funcionários

50

EBITDA

-2.7M

-3.8M

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-2.2M

36M

Abertura anterior

10.47

Fecho anterior

9.97

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Ekso Bionics Holdings Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de mar. de 2026, 23:31 UTC

Ações em Alta

Stocks to Watch: Nike, RH, NCino

31 de mar. de 2026, 22:35 UTC

Ganhos

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 de abr. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 de mar. de 2026, 23:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 de mar. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 de mar. de 2026, 23:33 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 de mar. de 2026, 23:21 UTC

Ganhos

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 de mar. de 2026, 23:14 UTC

Conversa de Mercado
Ganhos

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 de mar. de 2026, 23:12 UTC

Conversa de Mercado

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Loss Widens >000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 de mar. de 2026, 21:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 de mar. de 2026, 21:36 UTC

Conversa de Mercado

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 de mar. de 2026, 21:33 UTC

Ganhos

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 de mar. de 2026, 21:32 UTC

Ganhos

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 de mar. de 2026, 21:28 UTC

Ganhos

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 de mar. de 2026, 21:26 UTC

Ganhos

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 de mar. de 2026, 21:25 UTC

Ganhos

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 de mar. de 2026, 21:24 UTC

Conversa de Mercado
Ganhos

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 de mar. de 2026, 21:22 UTC

Ganhos

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 de mar. de 2026, 21:22 UTC

Ganhos

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 de mar. de 2026, 21:21 UTC

Ganhos

Nike's Digital Channel Still Too Promotional, CFO Says

31 de mar. de 2026, 21:20 UTC

Ganhos

Nike CEO: Converse Remains Important to Portfolio

Comparação entre Pares

Variação de preço

Ekso Bionics Holdings Previsão

Consenso de Avaliação

By TipRanks

0 ratings

0

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.4084 / 0.4998Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

No Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

help-icon Live chat